Burns (Dermatology) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Burns (Dermatology) – Drugs In Development, 2021, provides an overview of the Burns (Dermatology) pipeline landscape.

A burn is damage to body's tissues caused by heat, chemicals, electricity, sunlight or radiation. Symptoms include pain, increasing with each degree of burn, red and swollen skin, blisters and charred and blackened skin. Treatment includes antibiotics and pain relievers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Burns (Dermatology) – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Burns (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Burns (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Burns and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 3, 7, 1, 24, 7 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Burns (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Burns (Dermatology).

– The pipeline guide reviews pipeline therapeutics for Burns (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Burns (Dermatology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Burns (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Burns (Dermatology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Burns (Dermatology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Burns (Dermatology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Aegle Therapeutics Corp

AlgiPharma AS

Alliance Pharma Plc

Anterogen Co Ltd

Bioharmony Therapeutics Inc

Biomendics LLC

CFM Pharma Holding BV

Chrysalis BioTherapeutics Inc

Clene Inc

Combangio Inc

cStem Regeneration Pharmaceutical Co Ltd

Energenesis Biomedical Co Ltd

FirstString Research Inc

FortuneRock (China) Ltd

GNT Pharma Co Ltd

Hunan Sanqing Pharmaceutical Co Ltd

Hypo-Stream Ltd

Jupiter Wellness Inc

Madam Therapeutics BV

Table of Contents

Table of Contents

Introduction

Burns - Overview

Burns - Therapeutics Development

Burns - Therapeutics Assessment

Burns - Companies Involved in Therapeutics Development

Burns - Drug Profiles

Burns - Dormant Projects

Burns - Discontinued Products

Burns - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Burns, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Burns – Pipeline by Aegle Therapeutics Corp, 2021

Burns – Pipeline by AlgiPharma AS, 2021

Burns – Pipeline by Alliance Pharma Plc, 2021

Burns – Pipeline by Anterogen Co Ltd, 2021

Burns – Pipeline by Bioharmony Therapeutics Inc, 2021

Burns – Pipeline by Biomendics LLC, 2021

Burns – Pipeline by CFM Pharma Holding BV, 2021

Burns – Pipeline by Recce Pharmaceuticals Ltd, 2021

Burns – Pipeline by Regeneus Ltd, 2021

Burns – Pipeline by Rejuvenation Technologies Inc, 2021

Burns – Pipeline by Riptide Bioscience Inc, 2021

Burns – Pipeline by Se-cure Pharmaceuticals Ltd, 2021

Burns – Pipeline by Shulov Innovative Science Ltd, 2021

Burns – Pipeline by Stemsynergy Therapeutics Inc, 2021

Burns – Pipeline by TGV-Inhalonix Inc, 2021

Burns – Pipeline by Theragnostic Technologies Inc, 2021

Burns – Pipeline by TreeFrog Therapeutics SAS, 2021

Burns – Pipeline by USV Pvt Ltd, 2021

Burns – Pipeline by viDA Therapeutics Inc, 2021

Burns – Pipeline by Washburn Therapeutics Inc, 2021

Burns – Dormant Projects, 2021

Burns – Dormant Projects, 2021 (Contd..1)

Burns – Dormant Projects, 2021 (Contd..2)

Burns – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Burns, 2021

Number of Products under Development by Companies, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports